| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,068 |
981 |
$333K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,569 |
1,437 |
$274K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,268 |
1,190 |
$224K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
138 |
129 |
$85K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
264 |
257 |
$39K |
| 70450 |
Computed tomography, head or brain; without contrast material |
362 |
336 |
$33K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
18 |
16 |
$6K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,291 |
1,076 |
$2K |
| 80053 |
Comprehensive metabolic panel |
2,357 |
1,964 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
215 |
194 |
$785.50 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,010 |
803 |
$238.30 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
355 |
321 |
$146.96 |
| G0378 |
Hospital observation service, per hour |
29 |
14 |
$95.56 |
| 71045 |
Radiologic examination, chest; single view |
921 |
853 |
$59.52 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
248 |
231 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
929 |
836 |
$0.00 |
| 81025 |
|
384 |
358 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
321 |
305 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
617 |
583 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
711 |
616 |
$0.00 |
| 80305 |
|
73 |
69 |
$0.00 |
| 84100 |
|
222 |
183 |
$0.00 |
| 81003 |
|
1,260 |
1,149 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
67 |
54 |
$0.00 |
| 82977 |
|
182 |
175 |
$0.00 |
| 84702 |
|
14 |
13 |
$0.00 |
| 87400 |
|
183 |
177 |
$0.00 |
| 85610 |
|
13 |
12 |
$0.00 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
26 |
26 |
$0.00 |
| 85049 |
|
15 |
12 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
38 |
37 |
$0.00 |
| 71046 |
Radiologic examination, chest; 2 views |
26 |
25 |
$0.00 |
| 83605 |
|
618 |
487 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
563 |
506 |
$0.00 |
| 82150 |
|
359 |
340 |
$0.00 |
| 84484 |
|
648 |
562 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,200 |
1,912 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
125 |
98 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
359 |
339 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
102 |
94 |
$0.00 |
| 83735 |
|
687 |
590 |
$0.00 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,199 |
1,083 |
$0.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
111 |
106 |
$0.00 |
| 83880 |
|
72 |
65 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
840 |
793 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
57 |
52 |
$0.00 |
| 85379 |
|
64 |
60 |
$0.00 |
| 96376 |
|
110 |
84 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
21 |
16 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
15 |
15 |
$0.00 |